Pay in 4 interest-free payments of $5.66 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
All Rights MAKE AN ENQUIRY
Thats a genuinely interesting mechanistic story
This could be a good option to increase success rates for GLP-1 SUD treatment
370 The Phase 0 clinical study (NCT03020017) in eight patients with GBM showed that NU-0129 could pass through the BBB and accumulate in tumors, reducing the abundance of BCL2L12 protein and demonstrating its potential as an innovative therapy for GBM
Toxicol Appl Pharmacol 230(3):358363
US$ 29.69
US$ 24.27
US$ 20.85
US$ 23.80
